Journal of Clinical & Experimental OncologyISSN: 2324-9110

Reach Us +1 850 900 2634
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Can FDG PET/CT and CT Exclude N2 and N3 Nodal Disease in Patients with Breast Cancer?

Purpose: The purpose of this study was to investigate if PET-CT and CT were able to exclude N2 and N3 disease in patients with breast cancer.

Materials and Methods: In this study, the PET-CT reports of 211 patients who had been previously diagnosed with breast cancer and who had undergone PET-CT examinations and sentinel lymph node biopsies or axillary lymph node dissections, were reevaluated retrospectively. Whether PET-CT and CT were able to exclude N2 or N3 disease was the subject of evaluation of this study.

Results: It was found at the end of the study that PET-CT was able to exclude N2 and N3 involvement in 92,9 % of the cases, whereas CT alone could do the same exclusion in 93,6 %.

Conclusion: PET-CT and CT can well exclude N2 and N3 disease in patients with breast cancer. It may be suggested that PET-CT can replace sentinel lymph node biopsy in future preoperative evaluations.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations